SEK 117.0
(0.0%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 600 Thousand SEK | 8.11% |
2022 | 555 Thousand SEK | -94.43% |
2021 | 9.96 Million SEK | 135.93% |
2020 | 4.22 Million SEK | -43.76% |
2019 | 7.5 Million SEK | -0.74% |
2018 | 7.56 Million SEK | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q3 | 400 Thousand SEK | 0.0% |
2024 Q2 | 400 Thousand SEK | 0.0% |
2024 Q1 | 400 Thousand SEK | -33.33% |
2023 FY | 600 Thousand SEK | 8.11% |
2023 Q4 | 600 Thousand SEK | 20.0% |
2023 Q3 | 500 Thousand SEK | 0.0% |
2023 Q2 | 500 Thousand SEK | -16.67% |
2023 Q1 | 600 Thousand SEK | 8.11% |
2022 Q1 | 600 Thousand SEK | 0.0% |
2022 Q3 | 600 Thousand SEK | 0.0% |
2022 Q2 | 600 Thousand SEK | 0.0% |
2022 Q4 | 555 Thousand SEK | -7.5% |
2021 Q4 | - SEK | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
AroCell AB (publ) | - SEK | -Infinity% |
Immunovia AB (publ) | 1.78 Million SEK | 66.424% |
Prostatype Genomics AB (publ) | 67 Thousand SEK | -795.522% |
SenzaGen AB | 1.67 Million SEK | 64.136% |
Spermosens AB | 230 Thousand SEK | -160.87% |